Control of impurities

The guideline states that the objective of validation is to demonstrate that an analytical method is fit for its purpose and summarizes the characteristics required of tests for identification, control of impurities and assay procedures (Table 13-2). As such, it applies to chiral drug substances as to any other active ingredients. Requirements for other analytical procedures may be added in due course. 

Most samples may be prepared by dissolution in water. The final concentration should be optimized according to the aim of the analysis, counterion or impurity analysis. For the control of impurities, the main counterion may be fairly overloaded. This may have an impact on the ionic strength of the sample and will produce a disturbed peak profile for the main compound. When solubility problems are encountered, up to 30% of methanol, ethanol, or acetonitrile may be added to improve solubility. However, the presence of too much organic solvent may produce an instrumental error, because the conductivity of the sample plug will differ too much from BGE conductivity, leading to current leakage. Or, when the sample is insoluble in water, it may be suspended, vortexed, and then centrifuged. The analysis is then performed on the supernatant as the ions are water soluble. 

The aim of validation of an analytical procedure is to demonstrate that the method employed in any product testing, such as the identification, control of impurities, assay, dissolution, particle size, water content, or residual solvents, is validated in the most important characteristics. Identification tests, quantitative tests for impurities content, limit tests for control of impurities, and quantitative tests of the active moiety in samples of pharmaceutical product are the most common types of analytical procedures that validation addresses [1]. 

Erickson M. Identification and control of impurities in excipients. Am Pharm Rev 2005 88-94. 

The control of impurity release and transport requires a better understanding of the complex phenomena of plasma-wall interactions including the processes occuring in the scrape-off layer in the limiter shadow. In order to establish the feasibility of suggested solutions such as divertors or surface modifications, experiments have to be performed not only in the laboratory but also in-situ in fusion devices. The latter... 

The four most common types of analytical procedures are identification tests, including quantitative measurements for impurities, content, limit tests for the control of impurities, and quantitative measure of the active component or other selected components in the drug substance [18]. Table 1.3 describes the performance characteristics that should be evaluated for the common types of analytical procedures [18]. 

Finally, we analyzed the control implications of the presence of impurities in a process, concluding that the control of impurity levels must be addressed over an extended time horizon using the flow rate of the purge stream as a manipulated input. To close the impurity-levels loop, one should resort either to an appropriately tuned linear controller (e.g., a PI controller with long reset time) or to a (nonlinear) model-based controller that uses (an inverse of) the reduced-order model of the slow dynamics - as developed in this chapter - to compute the necessary control action. 

The quality of the EDC sent to pyrolysis must fulfil strict purity specifications, but too low an impurity level implies high energy consumption. The concentrations of T and I2 in the bottom of S2 must not exceed 100 and 600 ppm, respectively, while the concentration of I3 must be kept around its optimal value at 2000 ppm. It is worth mentioning that these contradictory requirements cannot be fulfilled by any standalone design of S2. The effective control of impurities becomes possible only by exploiting the positive-feedback effects of the recycle loops that are balanced by the negative-feedback effects of chemical conversion and exit streams. 

Regarding production of bulk drug substances, specifications for contaminants should be established for all solvents used in the process. A comparison should be performed between the manufacturer s Certificate of Analysis and the submitted specifications, and any discrepancies should be justified. A full description for the route of synthesis should be given, as this is important for the testing and control of impurities and process solvent residues. The FDA expects that, at the time of submission, it will be determined if the drug substance exists in a multiple solid state form (racemic mixture stereoisomer) and whether this affects the dissolution and bioavailability of the drug product. 

In its simplest form, steel is an alloy of iron and carbon. In general, there are other alloying elements present. Steel wires can vary in composition enormously, from simple C-Mn steel to alloy steels containing more than ten alloy additions. Control of impurities (mostly nonmetallic inclusions), chemical segregation,... 

---